Navigation Links
Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
Date:10/22/2007

Filed in Support of Federal Pre-Emption in Riegel v. Medtronic, Inc.

WASHINGTON, Oct. 22 /PRNewswire-USNewswire/ -- Leading a group of concerned organizations, the Advanced Medical Technology Association (AdvaMed) filed a joint amicus brief Friday in the U.S. Supreme Court in the matter of Riegel v. Medtronic, Inc. arguing that the FDA should continue to be the sole regulator of medical devices. The brief states that no other legislative or regulatory entity is better positioned than the Food and Drug Administration to ensure the timely access to safe and effective medical devices.

The brief also contends allowing a state-law liability approach to assessing safety and effectiveness would lead to reduced patient access to essential medical technologies.

Joining AdvaMed are DRI, Medmarc Insurance Group and the Medical Device Manufacturers Association.

"The safety and efficacy of medical technologies are best determined by FDA scientists -- not by lawsuits filed in courtrooms throughout the country. It was the specific intent of the U.S. Congress that the FDA be responsible for the timely approval of safe and effective medical technologies. Encouraging states to insert state court liability suits into the process would undermine the science-based approach to approvals currently in place and would likely result in inconsistencies in standards and delayed access to products," said Christopher White, AdvaMed Executive Vice President and General Counsel.

Two previous rulings in this case have made clear that the Medical Device Amendments (MDA) to the Federal Food Drug and Cosmetic Act (FDCA) expressly provides for FDA's ultimate regulatory authority in these matters.

"We hope the Supreme Court re-affirms the two previous lower court rulings and prevents any erosion in FDA's existing regulatory approval authority," said White.

Other key arguments made in the filing include:

-- FDA currently exercises substantial pre-marketing oversight of medical devices;

-- Enhanced state-law liability would interfere with FDA's extensive pre- and post-marketing oversight of medical devices, not fill a regulatory "gap";

-- State tort liability would stifle the innovation of important and life-saving medical devices and would undermine the affordability of medical treatments; and

-- State tort liability would encourage defensive labeling and over-warning that undermines rational prescribing by physicians.

Counsel for Amici Curiae include Daniel E. Troy, former Chief Counsel at the FDA, and Carter G. Phillips, former Assistant to the Solicitor General, both Partners at Sidley Austin LLP.

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. Our members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 50 percent purchased annually around the world. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit http://www.advamed.org.


'/>"/>
SOURCE Advanced Medical Technology Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. A brief Intervention Might Help To Deal With Depression
2. Brief Intervention on HIV and Alcohol Risk Encourages Safer Sex
3. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
4. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
5. Public Interest Litigation Filed Favoring Mineworkers Against Silicosis
6. Suit Filed Against Horrors of Psychiatric Ward in New York Hospital
7. Suit Filed Against Horrors of Psychiatric Ward in New York Hospital
8. Supreme Court Quashed Reservation Quotas For PG Medical Courses
9. Supreme Court Verdict Gives Hope to Striking Medicos
10. Supreme Court Warns Medicos of Contempt Action
11. Supreme Court Verdict Gives Hope to Striking Medicos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled ... wearable activity and sleep monitoring solutions for the global scientific community. The company’s ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology: